Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More

VSIG4 Rat anti-Mouse, APC, Clone: NLA14, eBioscience™ Non-distribution product as customer accommodation.

Rat Monoclonal Antibody

$119.00 - $332.00

Specifications

Antigen VSIG4
Clone NLA14
Target Species Mouse
Conjugate APC
Isotype IgG2a, kappa
View More Specs

Products 2
Catalog Number Mfr. No. Quantity Price Quantity & Availability  
Catalog Number Mfr. No. Quantity Price Quantity & Availability  
17-575-280 Non-distribution product as customer accommodation. View Documents Invitrogen
17575280
25 μg Each for $119.00
Add to cart
 
17-575-282 Non-distribution product as customer accommodation. View Documents Invitrogen
17575282
100 μg Each for $332.00
Add to cart
 
Description

Description

Description: This NLA14 monoclonal antibody recognizes mouse V-Set and Immunoglobulin domain containing 4 (VSIG4), also known as Complement Receptor of the Immunoglobulin superfamily (CRIg) or Z39Ig. VSIG4 is a type I transmembrane glycoprotein structurally related to the B7 family of immune regulatory proteins. It contains one complete V-type Ig domain and one truncated C-type Ig domain. VSIG4 is exclusively expressed on tissue resident and tumor infiltrating macrophages. It has been shown to bind complement components C3b and iC3b. This binding inhibits the alternative complement pathway and facilitates phagocytosis of complement-opsonized pathogens. VSIG4 has also been reported to suppress T cell activation, proliferation and IL-2 production thereby playing a role in the maintece of peripheral T cell tolerance and suppression of established inflammation. Expression of VSIG4 on tumor-infiltrating macrophages suggests its role in immune evasion. Pro-inflammatory stimuli such as TNF and LPS have been reported to down-regulate the expression of VSIG4. Peritoneal macrophages in Balb/c mice express significantly higher levels of VSIG4 than such macrophages in C57Bl/6 or Swiss Webster mice. The NLA14 antibody will recognize VSIG4 on cells that have been formaldehyde-fixed and permeabilized. This antibody does not block the ligation of VSIG4 to its T cell ligand. The NLA14 antibody does not cross-react with rat or human VSIG4.

Applications Reported: This NLA14 antibody has been reported for use in flow cytometric analysis. Applications Tested: This NLA14 antibody has been tested by flow cytometric analysis of mouse peritoneal exudate cells. This can be used at less than or equal to 0.5 µg per test. A test is defined as the amount (µg) of antibody that will stain a cell sample in a final volume of 100 µL. Cell number should be determined empirically but can range from 10^5 to 10^8 cells/test. It is recommended that the antibody be carefully titrated for optimal performance in the assay of interest. Excitation: 633-647 nm; Emission: 660 nm; Laser: Red Laser. Filtration: 0.2 µm post-manufacturing filtered. T cell activation by APCs is positively and negatively regulated by members of the B7 family. VSIG4 is a strong negative regulator of murine and human T cell proliferation and IL-2 production.
Specifications

Specifications

VSIG4
Mouse
IgG2a, kappa
Monoclonal
Liquid
Antibody
4° C, store in dark, DO NOT FREEZE!
NLA14
APC
Flow Cytometry
Primary
Monoclonal
PBS with 0.1% gelatin and 0.09% sodium azide; pH 7.2
RUO

For Research Use Only

Provide Content Correction

The Fisher Scientific Encompass Program offers items which are not part of our distribution portfolio. These products typically do not have pictures or detailed descriptions. However, we are committed to improving your shopping experience. Please use the form below to provide feedback related to the content on this product.

Product Title

By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.

Cancel Submit